Pharmicell

At a glance

Pharmicell filed 44 disclosures in the last 12 months, including 8 insider, 5 contract, 5 5% holder and 1 issuance. The most recent key filing was on Oct 14: Worth 6.5% of last year's revenue, over about 3 months.

Revenue for 2025 was ₩114B, up 75.9% on 2024. Operating margin was 30.1% against 7.2% a year earlier. Debt was 27% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩75.7B and operating profit of ₩26.3B.

The 2025 annual report lists 186 employees with an average tenure of 5.3 years and average pay of ₩71.7M, #556 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩266M each on average. It paid ₩50 per common share in cash dividends, against ₩20 a year earlier (+150%). 김현수 and related parties held 9.36% at year end.

From the 2025 annual report

Staff: 186 (144 men, 42 women), of whom 3 on fixed-term contracts. Total pay for the year: ₩13.4B. Directors and auditors: 7, paid ₩1.9B in total.

Dividends (common shares)

Largest shareholder

김현수 holds 8.82%; with 6 related parties the group holds 9.36% of common shares at year end (from 9.33% at the start of the year).

Individuals paid ₩500M or more

Auditor: 우리회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Rankings: Operating margin #22 of 1,376 · Revenue growth #34 of 1,376

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

2 new supply contracts worth 13% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary